Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Rhea-AI Summary
Ardelyx (Nasdaq: ARDX) announced it will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
Investors can access a live webcast and replay via the Ardelyx investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – ARDX
In the May 19 session, ARDX declined 0.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Clinical data update | Positive | -1.7% | Post hoc analysis showed long-term XPHOZAH safety with no meaningful electrolyte issues. |
| Apr 30 | Earnings and update | Positive | +8.7% | Q1 2026 revenue growth, strong IBSRELA sales, reaffirmed 2026 product guidance and pipeline progress. |
| Apr 27 | Conference poster | Positive | +0.7% | NKF poster acceptance on long-term XPHOZAH data and sponsored peer exchange on therapy use. |
| Apr 23 | Conference abstract | Neutral | -1.0% | DDW 2026 poster and product theater focused on IBS-C treatment patterns and education. |
| Apr 20 | Leadership change | Neutral | -2.3% | Appointment of new Chief Legal Officer succeeding long‑tenured predecessor across legal and compliance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news flow has been mostly positive or neutral, yet price reactions have been mixed, with several scientific or corporate updates coinciding with mild pullbacks.
Over the last month, Ardelyx has reported multiple medical and corporate milestones, including long-term XPHOZAH safety data on May 7, 2026 and Q1 2026 results on April 30, 2026 highlighting strong product revenue growth and reaffirmed guidance. Additional abstracts at NKF and DDW and a new Chief Legal Officer appointment rounded out the news flow. These prior events show a blend of positive fundamentals and mixed day‑after price reactions, framing today’s conference participation as part of an ongoing visibility and stakeholder-engagement strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
To access the live webcast of the fireside chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available following the event.
About Ardelyx, Inc.
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize our products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor & Media Contact:
Lisa Caperelli
lcaperelli@ardelyx.com
